ArticleDiabetes care2018
SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Article in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06894784 (Semaglutide And Empagliflozin Combination Therapy Added To Automated Insulin Delivery In Adults With Type 1 Diabetes), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Semaglutide And Empagliflozin Combination Therapy Added To Automated Insulin Delivery In Adults With Type 1 Diabetes (SEMPA)
Who cites it
8 citing papers in PubMed.
- Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.Diabetes, obesity & metabolism · 2020Trial
- Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination.TouchREVIEWS in endocrinology · 2021Review
- The Current and Potential Therapeutic Use of Metformin-The Good Old Drug.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor.Diabetes spectrum : a publication of the American Diabetes Association · 2021Article
- Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?Cureus · 2020Review
- The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition.Diabetes · 2020Article
- Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Review
- A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetes.Metabolism open · 2020Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30459245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.